13F-HR filed by NOVO HOLDINGS A/S
NOVO HOLDINGS A/S filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-14, with 27 holding rows worth $1,551,582,935.
- Accession
- 0001388325-25-000025
- Filer
- CIK 1388325
- Filed
- 2025-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2025
A holdings report, 27 entries on the cover page, a total value of $1,551,582,935 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,551,582,935 with VALUE read as dollars as filed, 13F file number 028-16231. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| VTI | 922908769 | COM | 1,038,550 | $340,820,954 | dollars as filed | |
| BROOKFIELD CORP CL A LTD VT SH | 11271J107 | Stock | 2,330,830 | $159,848,321 | dollars as filed | |
| ASMLHLDGNVFSPONSOREDADR1ADRREPS1ORDSHS | N07059210 | STOK | 145,836 | $141,182,373 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 1,264,028 | $92,665,893 | dollars as filed | |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 5,350,000 | $86,777,000 | dollars as filed | |
| Salesforce.com, Inc | 79466L302 | COM | 330,187 | $78,254,319 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 750,000 | $70,612,500 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 1,625,000 | $67,681,250 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 2,380,000 | $51,360,400 | dollars as filed | |
| ALIBABA GROUP HLDG LTD | 01609W102 | SPONSORED ADS | 257,327 | $45,992,055 | dollars as filed | |
| ZENAS BIOPHARMA INC COM | 98937L105 | Stock | 2,000,000 | $44,400,000 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 1,750,000 | $43,662,500 | dollars as filed | |
| RECURSION PHARMACEUTICALS IN | 75629V104 | CL A | 7,929,835 | $38,697,595 | dollars as filed | |
| ARRIVENT BIOPHARMA INC | 04272N102 | COM | 1,942,142 | $35,832,520 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 660,000 | $35,745,600 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 916,160 | $33,000,083 | dollars as filed | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 1,200,000 | $31,044,000 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 1,426,260 | $29,195,542 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 200,000 | $28,802,000 | dollars as filed | |
| Valneva SE ADR | 92025Y103 | COM | 2,345,000 | $28,609,000 | dollars as filed | |
| BRIDGEBIO ONCOLOGY THERAPEUT | 107924102 | COM NEW | 1,961,317 | $22,712,051 | dollars as filed | |
| APOGEE THERAPEUTICS INC COM | 03770N101 | Stock | 500,000 | $19,865,000 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 2,000,000 | $17,380,000 | dollars as filed | |
| LANZATECH GLOBAL INC | 51655R200 | CMN | 158,148 | $3,876,207 | dollars as filed | |
| MARQETA INC | 57142B104 | CLASS A COM | 441,558 | $2,331,426 | dollars as filed | |
| IO BIOTECH INC | 449778109 | COM | 2,512,453 | $912,272 | dollars as filed | |
| DAMORA THERAPEUTICS INC | 36322Q206 | COMMON STOCK | 86,579 | $322,074 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001388325-25-000025 | this filing | 2025-11-14 | acceptance time not in the bulk data set |